Engineered immune cells take on autoimmune diseases in early trial
NCT ID NCT07167537
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial is testing a new treatment called OL-CD19-GDT, which uses specially engineered immune cells (CAR-T cells) from a healthy donor to target and destroy faulty immune cells in people with severe autoimmune diseases like systemic sclerosis and Sjogren's syndrome. The study will enroll 44 adults whose disease has returned or not responded to standard treatments. The main goals are to check the treatment's safety and find the right dose, while also looking at how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OL-CD19-GDT (allogeneic CAR-T cells targeting CD19)
What this could lead to
If successful, this could offer a new treatment option for people with severe autoimmune diseases that haven't responded to standard therapies.
What could go wrong
This is a very early (Phase 1) trial with only 44 participants, so safety and effectiveness are not yet proven. CAR-T therapy can cause serious side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, 102206, China